Answers are grounded in this paper and cite their sources.
Network meta-analysis demonstrates that adjunct intra-arterial thrombolysis improves outcomes in acute ischemic stroke, suggesting further study is needed.
Background: The benefit of adjunct intra-arterial (IA) thrombolysis post endovascular thrombectomy (EVT) for acute ischemic stroke remains unclear. We aim to compare the efficacy and safety of IA thrombolytic agents used in post-EVT, with particular attention to dose variation. Methods: We included randomized controlled trials of adult patients with large-vessel occlusion stroke that compared EVT alone with EVT plus IA thrombolysis. PubMed, Scopus, Embase, and the Cochrane Library were searched for relevant studies (up to 10/08/2025). The primary outcome was excellent functional recovery (modified Rankin Scale [mRS] 0–1 at 90 days). Safety outcomes were intracerebral hemorrhage (ICH) and 90-day mortality. Odds ratios were calculated using a random-effects frequentist network meta-analysis with the DerSimonian Laird estimator. Language refinement was assisted by ChatGPT (OpenAI, GPT-5). Results: Eight RCTs (n=2,148) informed functional independence (mRS 0–1 at 90 days). Compared with EVT alone, EVT plus intra-arterial alteplase 0.225 mg/kg significantly improved functional independence (OR 1.98, 95% CI 1.35–2.92, p=0.0005), and EVT plus Tenecteplase 0.125 mg/kg also showed benefit (OR 1.90, 95% CI 1.12–3.23, p=0.017). Other regimens did not achieve statistical significance. For safety, seven RCTs (n=1,844) demonstrated no increased risk of intracerebral hemorrhage with IA agents (e.g., alteplase OR 0.27, 95% CI 0.03–2.15; urokinase OR 1.00, 95% CI 0.43–2.35), while IA tenecteplase 0.0625 mg/kg showed a nonsignificant trend toward higher ICH (OR 1.76, 95% CI 0.94–3.28; p=0.076; I^2=0%). Six RCTs (n=1,804) demonstrated no significant mortality difference across IA thrombolysis regimens compared with EVT alone. Heterogeneity and inconsistency were low across analyses (I^2 = 0%). Conclusions: Adjunctive IA Alteplase and Tenecteplase after EVT improved functional recovery with no increase in ICH or mortality, and higher dose Tenecteplase appeared to yield a superior outcome compared to lower dose, underscoring the need for larger trials to refine optimal regimens.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: